Cardiovascular and Noncardiovascular Prescribing and Mortality After Takotsubo

• DOI: 10.1016/j.jacadv.2023.100797
• Publication Date: 2024-01-10T18:56:20Z
• Authors: Amelia E. Rudd; Graham Horgan; Hilal Khan; David T. Gamble; Jim McGowan; Arvind Sood; Ross McGeoch; John Irving; Jonathan Watt; Stephen J. Leslie; Mark Petrie; Chim Lang; Nicholas L. Mills; David E. Newby; Dana K. Dawson
• Keywords: Takotsubo Syndrome

Takotsubo syndrome is an increasingly common cardiac emergency with no known evidence-based treatment. The purpose of this study was to investigate cardiovascular mortality and medication use after takotsubo syndrome. In a case-control study, all patients in Scotland between 2010 2017 (n = 620) were age, sex, geographically matched individuals the general population (1:4, n 2,480) contemporaneous acute myocardial infarction (1:1, 620). Electronic health record data linkage outcomes drug prescribing analyzed using Cox proportional hazard regression models. Of 3,720 participants (mean 66 years; 91% women), 153 (25%) died over median 5.5 years follow-up. This exceeded rates (N 374 [15%]; HR: 1.78 [95% CI: 1.48-2.15], P < 0.0001), especially for (HR: 2.47 1.81-3.39], 0.001) but also noncardiovascular 1.48 1.16-1.87], 0.002) deaths. Mortality lower than those (31%, 195/620; 0.76 0.62-0.94], 0.012), which attributable 0.61 0.44-0.84], not 0.92 0.69-1.23], 0.59) Despite comparable medications use, therapies consistently associated better survival Diuretic (P 0.01), anti-inflammatory 0.002), psychotropic worse syndrome, leading cause death, therapy use.